Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Junting Zhou, Xueyang Jiang, Siyu He, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 20, pp. 8881-8914
Closed Access | Times Cited: 232

Showing 1-25 of 232 citing articles:

Polypharmacology: The science of multi-targeting molecules
Abbas Kabir, Aaron Muth
Pharmacological Research (2022) Vol. 176, pp. 106055-106055
Closed Access | Times Cited: 100
Molecular hybridization: a powerful tool for multitarget drug discovery
Pedro de Sena Murteira Pinheiro, Lucas Silva Franco, Tadeu L. Montagnoli, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 451-470
Closed Access | Times Cited: 39
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
Claudia Albertini, Alessandra Salerno, Pedro de Sena Murteira Pinheiro, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 5, pp. 2606-2633
Closed Access | Times Cited: 127
Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
Xiangqian Li, Xiaowei Li, Fang Liu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10581-10605
Closed Access | Times Cited: 101
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease
Michele Rossi, Michela Freschi, Luciana de Camargo Nascente, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 8, pp. 4972-4990
Open Access | Times Cited: 88
Advancements in the development of multi-target directed ligands for the treatment of Alzheimer’s disease
Naveen Kumar, Vijay Kumar, Piyush Anand, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 61, pp. 116742-116742
Closed Access | Times Cited: 66
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
Zhao Wang, Srinivasulu Cherukupalli, Minghui Xie, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3729-3757
Open Access | Times Cited: 50
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
Yue Zhong, Fanglian Chi, Hanyu Wu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 231, pp. 114142-114142
Closed Access | Times Cited: 40
Ceramides and ceramide synthases in cancer: Focus on apoptosis and autophagy
Javad Alizadeh, Simone C. da Silva Rosa, Xiaohui Weng, et al.
European Journal of Cell Biology (2023) Vol. 102, Iss. 3, pp. 151337-151337
Open Access | Times Cited: 38
First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease
Patryk Pyka, Wawrzyniec Haberek, Małgorzata Więcek, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1580-1610
Open Access | Times Cited: 12
Explore new quinoxaline pharmacophore tethered sulfonamide fragments as in vitro α‐glucosidase, α‐amylase, and acetylcholinesterase inhibitors with ADMET and molecular modeling simulation
Ahmed Ragab, Mohamed A. Salem, Yousry A. Ammar, et al.
Drug Development Research (2024) Vol. 85, Iss. 4
Closed Access | Times Cited: 10
Design, synthesis, in vitro and in silico evaluations of new isatin-triazine- aniline hybrids as potent anti- Alzheimer multi-target directed lead compounds
Yasaman Tamaddon-Abibigloo, Siavoush Dastmalchi, Nima Razzaghi‐Asl, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107355-107355
Closed Access | Times Cited: 9
Terpenes as Potential Anti-Alzheimer’s Disease Agents
Elisabete Lima, Jorge Medeiros
Applied Sciences (2024) Vol. 14, Iss. 9, pp. 3898-3898
Open Access | Times Cited: 9
Dual Inhibitors of Brain Carbonic Anhydrases and Monoamine Oxidase-B Efficiently Protect against Amyloid-β-Induced Neuronal Toxicity, Oxidative Stress, and Mitochondrial Dysfunction
Simone Giovannuzzi, Daniel Chavarria, Gustavo Provensi, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 4170-4193
Closed Access | Times Cited: 8
Network Pharmacology Approach to Identify the Calotropis Phytoconstituents’ Potential Epileptic Targets and Evaluation of Molecular Docking, MD Simulation, and MM‐PBSA Performance
Punam Salaria, Amarendar Reddy M
Chemistry & Biodiversity (2024) Vol. 21, Iss. 5
Closed Access | Times Cited: 8
An up-to-date overview of computational polypharmacology in modern drug discovery
Rajan Chaudhari, Lon Wolf R. Fong, Zhi Tan, et al.
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 9, pp. 1025-1044
Open Access | Times Cited: 64
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease
Francesco Mesiti, Daniel Chavarria, Alexandra Gaspar, et al.
European Journal of Medicinal Chemistry (2019) Vol. 181, pp. 111572-111572
Closed Access | Times Cited: 57
Further insight into the dual COX-2 and 15-LOX anti-inflammatory activity of 1,3,4-thiadiazole-thiazolidinone hybrids: The contribution of the substituents at 5th positions is size dependent
Yasser M. Omar, Samia G. Abdel‐Moty, Hajjaj H.M. Abdu-Allah
Bioorganic Chemistry (2020) Vol. 97, pp. 103657-103657
Closed Access | Times Cited: 57
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model
Feng He, C. James Chou, Matthias Scheiner, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 3794-3812
Open Access | Times Cited: 49
Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective
Antonino N. Fallica, Valeria Pittalà, Maria Modica, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 7926-7962
Open Access | Times Cited: 46
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review
Zahra Haghighijoo, Leila Zamani, Fatemeh Moosavi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113949-113949
Closed Access | Times Cited: 46
Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010–2020)
Yunheng Li, Shenghu Sang, Weijie Ren, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113874-113874
Closed Access | Times Cited: 44
Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir
Santosh Kumar Behera, Nazmina Vhora, Darshan Contractor, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 43
Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
Anna Sampietro, F. Javier Pérez-Areales, Paula Felippe Martinez, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 545-545
Open Access | Times Cited: 32
Design, Synthesis, and Pharmacological Evaluation of N-Propargylated Diphenylpyrimidines as Multitarget Directed Ligands for the Treatment of Alzheimer’s Disease
Bhupinder Kumar, Ashish Ranjan Dwivedi, Tania Arora, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 14, pp. 2122-2139
Closed Access | Times Cited: 31
Page 1 - Next Page

Scroll to top